News
US Companies Seize Greater Control over Key Technologies in Robot-Assisted Surgery
Published: May 18,2015R&D Intensity of the Top 30 Patent Assignees
According to MIC (Market Intelligence & Consulting Institute), US and European vendors both have great R&D capabilities in medical robot. Out of the top 30 vendors who have relatively strong R&D intensity, 21 are based in the United States, four in Europe and five in the rest of the world.
ChatGPT to Drive Orders for Servers Equipped with AI Accelerator Cards: MIC
Since opening to the public at the end of 2022, ChatGPT`s user base has continued to grow, surpassing 100 million users. Driven by ChatGPT...
Taiwanese Manufacturing industry Concerned about IT Security
TAIPEI, Taiwan - Taiwan's IT research institute MIC (Market Intelligence & Consulting Institute) conducted surveys in la...
US vendors have a greater presence in robot-assisted surgery. Of all the 967 patents related to this application, US vendors controlled 920 pieces (95.1%) while European vendors only had 47 pieces (4.9%). Important technology fields include Surgical Instrument, Robotic Arm, Minimally Invasive, Surgical Tool, Image Data, Image Capture Device, Optical Fiber, and Light Source.
By contrast, European vendors have greater strength than US vendors in therapy robots. Of the 40 patents related to the field, European vendors owned 35 pieces (87.5%) while US vendors had five pieces (12.5%). Key technology fields include: X-ray, Radiation Therapy, and Electron Beam.
By pouring more resources into robot-assisted surgery, US vendors have demonstrated ambition to seize more control over the key technologies and be the front-runner in the market. By contrast, European vendors focus more on developing therapy robots. Perspective vendors are suggested to keep an eye on the latest development of the US and European incumbents.
CTIMES loves to interact with the global technology related companies and individuals, you can deliver your products information or share industrial intelligence. Please email us to en@ctimes.com.tw
1129 viewed